‘Big Pharma’ backs Trump’s Asia trade squeeze
Source: ASIA TIMES | May 03, 2018 US President Donald Trump’s administration stands accused of deploying bullying tactics to promote greater market access for American pharmaceutical companies by...
View ArticleLIES, DISTORTIONS, AND FALSE PROMISE: THE U.S. POSITION ON COMPULSORY...
Source: infojustice.org | May 1, 2018 Every year since the late 1980s, the U.S. has published a Special 301 Watchlist targeting countries that U.S. intellectual property-based industries, like Big...
View ArticleWhy India may not be able to ignore USTR’s 2018 Special 301 report
Source : Business Line | May 1, 2018 The United States Trade Representative has, in its “2018 Special 301 Report”, placed India on the “priority watch list”, again. A move that has been labelled ‘anti...
View ArticleUSTR Priority Watch List calls out countries for protecting public health
Source: MSF Access | April 27, 2018 NEW YORK, APRIL 27, 2018-The Office of the United States Trade Representative (USTR) released its annual “Special 301 Report” today, which reviews countries based on...
View ArticleThe scalpels are out ahead of ‘Special 301’ Report
by PT Jyothi Datta | The HinduBusinessLine Indian pharma pushes back against US trade body’s criticism of its IPR protection record For the past five years, a lone Indian pharmaceutical representation...
View ArticleClik here to view.
Section 301: US investigates allegations of forced technology transfers to China
Source: EastAsia Forum Authors: Zhiyao (Lucy) Lu and Gary Clyde Hufbauer, Peterson Institute for International Economics On 18 August 2017, the Trump administration invoked Section 301 of the Trade Act...
View ArticleClik here to view.
The Trump Executive Order on drug prices: not what was promised nor needed,...
Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on...
View ArticleClik here to view.
June 2017 Alert: Pressure on countries hiked by US on IP
The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include...
View ArticleClik here to view.
US continue to bully India – Place India again in Special 301 Priority Watch...
Yet again, USTR places India on its Priority Watch List in Special report 301 stating the lack of sufficient measurable improvements to its IP framework that negatively affects U.S. right holders...
View ArticleClik here to view.
Panel Rejects Eli Lilly Claim Over Canadian Patent Law, Orders Company to Pay...
In the early 1990s, Eli Lilly applied for patent protection in Canada for two chemical compounds, olanzapine and atomoxetine. The company had already obtained patents over the compounds, but asserted...
View ArticleClik here to view.
Indian pharma at odds with US trade group over USTR Priority Watch List
The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List –...
View ArticleClik here to view.
US continues to keep India on intellectual property priority watch list
By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of...
View ArticleClik here to view.
On IP Protection, USTR Finds Fault With China, India … And Switzerland?
BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns...
View ArticleClik here to view.
US Special 301 inconsistent with WTO rules, says India
Source: Hindu BusinessLine | APRIL 25, 2016 India has said that the US Special 301 report, which tries to put pressure on countries to enhance their intellectual property rights (IPRs) legislation,...
View ArticleClik here to view.
Nothing Special (301) to report
The annual IP report is expected soon By KM Gopakumar, The Hindu BusinessLine The Special 301 Report, an annual feature from the US that evaluates global intellectual property (IP) protection and...
View ArticleClik here to view.
U.S. industry body says India agreed to not issue ‘compulsory’ drug licences
By Zeba Siddiqui, Reuters|March 9, 2016 India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western...
View ArticleClik here to view.
Compulsory licensing: India gave ‘private reassurance’, says US business council
In a review submitted to USTR, four US industry bodies have said that India has developed a “positive” approach over the compulsory licensing issue. Written by Liz Mathew, The Indian Express | New...
View ArticleClik here to view.
Eli Lilly bats for a favourable patent regime in India
Eli Lilly wants a more favourable patent regime that ‘rewards innovation’ and would welcome an open dialogue from the government in this respect New Delhi: Global pharma company Eli Lilly wants a more...
View ArticleClik here to view.
PhRMA Special 301 submission 2016
PhRMA Special 301 Submission 2016 insists that India remains on the Priority Watch List in the USTR Special 301 Report. PhRMA sees India’s progressive Patent Act of 2005 and IP environment as a legal...
View ArticleClik here to view.
US pharma body slams Indian patent regime
Rupali Mukherjee, TNN | Feb 9, 2016 Mumbai: Criticizing India’s “weak” intellectual property rights (IPR) regime, PhRMA (Pharmaceutical Research and Manufacturers of America), which represents leading...
View Article
/pic9814888.png)
/fit-in/580x348/filters:format(webp)/english-betterindia/media/media_files/2026/09/17/balaghat-3-2026-09-17-18-46-40.png)
